Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948114 | 1.00 | PKN1 (0.38) | PKN1PKN2KDM4EPKMLDHA | |
| SCHEMBL23529329 | 0.94 | PKN1 (0.37) | PKN1PKN2 | |
| SCHEMBL23529304 | 0.90 | ACSS2 (0.39) | PKN1PKN2KDM4EPKM | |
| SCHEMBL29948221 | 0.90 | ACSS2 (0.39) | PKN1PKN2KDM4EPKM | |
| SCHEMBL23552644 | 0.90 | PKN1 (0.35) | PKN1PKN2 | |
| SCHEMBL23529311 | 0.88 | AGTR1 (0.42) | — | |
| SCHEMBL25095192 | 0.87 | PKN1 (0.33) | PKN1PKN2 | |
| SCHEMBL23529396 | 0.85 | GPR35 (0.35) | PKN1PKN2 | |
| SCHEMBL29948116 | 0.85 | GPR35 (0.35) | PKN1PKN2 | |
| SCHEMBL23552631 | 0.85 | PKN1 (0.34) | PKN1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | disclosed |
| WO-2022266711-A1 | SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS | Aculeus Therapeutics Pty Ltd (AU) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062932-A1 | COMPOUNDS | STING1, IRF3, MAVS | PKN1 2987/4885PKN2 3800/4885KDM4E 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.